AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23851972
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) as an adjunct to usual care
Trial: 22240882
Drug: Total occlusive
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total occlusive ionic silver‐containing dressing (TOISD) combination
Trial: 9236571
Drug: Tacrine hydrochloride
RxNorm normalized name: Tacrine Hydrochloride
DrugBank: Tacrine (DB00382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrine hydrochloride (160 mg/d)
Trial: 3652281
Drug: Pipemidic acid
RxNorm normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipemidic acid (two 200 mg doses daily for 7 days)
Trial: 31065701
Drug: DAILY (every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAILY (every day feeding)
Trial: 25136887
Drug: IV bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus regadenoson injection (400 µg)
Trial: 10817799
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg intravenous administration)
Trial: 9007147
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills (OCP) administered for 28-42 days followed by menotropin treatment
Trial: 1800877
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of fentanyl combined with diazepam
Trial: 30849239
Drug: 140 ml
RxNorm normalized name: syringe, disposable, 140 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 ml of 'BEET It sport®' NO3‐ shot
Trial: 31062253
Drug: gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin 300 mg
Trial: 19393845
Drug: acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 1000 mg
Trial: 27787564
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules (72 mg total, equivalent to 20 ounces of cranberry juice) administered once a day
Trial: 27787564
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once a day
Trial: 11207693
Drug: 585 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 585 nm pulsed dye laser treatment
Trial: 10757250
Drug: Lorazepam 1
RxNorm normalized name: lorazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1 mg
Trial: 30047564
Drug: Sofosbuvir (SOF)
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir (SOF) and Velpatasvir (VEL) quantified using a novel LC–MS/MS method; dosage and duration not specified.
Trial: 11196405
Drug: Fall‐Asleep Pacifier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fall‐Asleep Pacifier (FAP) with fluoride tablets (Fludent, containing NaF 0.25 mg, xylitol 159 mg, sorbitol 153 mg)
Trial: 11196405
Drug: Fluoride tablets
RxNorm normalized name: Sodium Fluoride Tablets
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride tablets (Fludent) crushed in food
Trial: 11196405
Drug: Fall‐Asleep Pacifier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fall‐Asleep Pacifier (FAP) with fluoride tablets (Fludent)
Trial: 31758195
Drug: Colistin-meropenem combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin-meropenem combination therapy
Trial: 30476654
Drug: Colistin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin monotherapy
Trial: 28734907
Drug: Oral second
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral second generation antipsychotic
Trial: 25020050
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose MenC‐TT at 3 months
Trial: 25020050
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 doses of MenC‐CRM197
Trial: 25020050
Drug: No primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No primary MenC doses
Trial: 20397594
Drug: Manipulated information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulated information about an agent's mental intentions
Trial: 8624384
Drug: Modification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modification of antibiotic therapy
Trial: 25754845
Drug: No mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mechanical bowel preparation (no MBP)
Trial: 22268969
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of isoflavones daily from Soylife 40
Trial: 21072892
Drug: Regular liver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular liver treatment only
Trial: 18765394
Drug: Percutaneous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous continuous aortic flow augmentation (flow ≤1.5 L/min for up to 96 hours) plus medical therapy
Trial: 15772912
Drug: Alvimopan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan 0.5 mg
Trial: 27996371
Drug: Combined maneuver
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined maneuver (injection of local anesthesia at the incision site, low‐pressure pneumoperitoneum, active gas suction, and pulmonary recruitment)
Trial: 22033001
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group 4) - no haemostatic agent applied
Trial: 36118
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg prenalterol
Trial: 36118
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg prenalterol
Trial: 28229390
Drug: 0.3 g·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g·kg‐1 body mass NaHCO3 (SBC3a and b)
Trial: 23587162
Drug: Peretinoin 600
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peretinoin 600 mg daily
Trial: 17078309
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) treatment
Trial: 10762505
Drug: Nasal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal continuous positive airway pressure (NCPAP) treatment during the first night
Trial: 20919542
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a hypercalorie formula and a fiber‐containing formula with erythromycin stimulation within the first 3 days.
Trial: 2210865
Drug: IgG-anti-LPS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG-anti-LPS therapy
Trial: 412207
Drug: Atenolol =
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol = 50 mg t.d.s.
Trial: 412207
Drug: Methyl dopa
RxNorm normalized name: Methyl dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl dopa = 250 mg t.d.s.
Trial: 28092069
Drug: Antimuscarinics and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinics and beta‐3 adrenergic agonists (alone or in combination with standard BPE/BPO therapy)
Trial: 28092069
Drug: Standard alpha‐adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard alpha‐adrenergic blockade and 5‐alpha reductase inhibitor therapy
Trial: 21561398
Drug: Memantine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine plus rivastigmine patch
Trial: 16430026
Drug: Citalopram-ratiopharm film-coated
RxNorm normalized name: citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram-ratiopharm film-coated tablets (test preparation)
Trial: 16430026
Drug: Tablets of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of a reference preparation (control)
Trial: 12793516
Drug: Manual Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Assisted Cognitive-Behaviour Therapy (MACT)
Trial: 3079010
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg three times daily
Trial: 2711919
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for 2 weeks
Trial: 1514339
Drug: Thiopentone 4
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 4 mg/kg
Trial: 889650
Drug: Althesin 0.055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Althesin 0.055 ml/kg
Trial: 861118
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg/kg
Trial: 889650
Drug: Pethidine 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 0.7 mg/kg after intubation
Trial: 27335011
Drug: Tracer group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tracer group (1 ml carbon nanoparticle suspension)
Trial: 708150
Drug: GOBA 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOBA 1.0 g
Trial: 26035319
Drug: HBV monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV monotherapy with either lamivudine or emtricitabine, N=56
Trial: 18030086
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluoxetine and CBT
Trial: 19723787
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment during follow-up (naturalistic follow-up)
Trial: 23896011
Drug: Acetaminophen 1
RxNorm normalized name: acetaminophen 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1 g
Trial: 16698862
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg + Acetaminophen 1 g
Trial: 14507834
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored IVM treatments (control group)
Trial: 10775962
Drug: Nicardipine (intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (intravenously 5 mg/hour for one week)
Trial: 1331482
Drug: High-dose carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose carboplatin and etoposide with autologous bone marrow transplantation plus oxazaphosphorine (usually cyclophosphamide)
Trial: 3858229
Drug: Xylitol-containing dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol-containing dentifrice (10% xylitol) with conventional treatment
Trial: 3858229
Drug: Fluoride systemic
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride systemic administration (in milk or drinking water) with conventional treatment
Trial: 3858229
Drug: Conventional dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dental treatment procedures alone (fluoride-free dentifrices)
Trial: 10386022
Drug: PVP-I nasal
RxNorm normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PVP-I nasal inhalation and gargling (1% PVP-I solution, 2 times/day for 2 weeks)
Trial: 11718517
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg zopiclone
Trial: 30609439
Drug: TG-C (TissueGene-C)
RxNorm normalized name: TG-C
DrugBank: TG-C (DB06004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG-C (TissueGene-C) at a dose of 3.0 × 10^7 cells
Trial: 21422117
Drug: AS03-adjuvanted influenza
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted influenza H1N1/A/09 vaccine (1 dose)
Trial: 21422117
Drug: AS03-adjuvanted influenza
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted influenza H1N1/A/09 vaccine (2 doses)
Trial: 16598442
Drug: nCPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP treatment in hypertensive OSAS patients
Trial: 15381595
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of intravenous amoxicillin‐clavulanic acid
Trial: 10703931
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (2 IU/m2/day = 0.67 mg/m2/day)
Trial: 8397723
Drug: L-dihydroxy-phenylalanine/carbidopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dihydroxy-phenylalanine/carbidopa (100 mg/25 mg)
Trial: 1902404
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin therapy
Trial: 11770190
Drug: Climodien (estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climodien (estradiol valerate 2 mg plus dienogest 2 mg)
Trial: 2941206
Drug: Prazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2 or 4 mg/day)
Trial: 2941206
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 or 80 mg/day)
Trial: 29506970
Drug: Creatine Monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine Monohydrate 15 g daily
Trial: 29506970
Drug: Creatine Monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine Monohydrate (10 g or 15 g)
Trial: 27437723
Drug: Mirror Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror Therapy (MT group, n=9), therapy with a mirror box 5 days/week, 30 min/day, for 3 weeks
Trial: 27437723
Drug: Electromyography-triggered neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromyography-triggered neuromuscular stimulation (ES group, n=7), therapy of similar duration and frequency as MT group
Trial: 25493602
Drug: PrEP (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among women using DMPA
Trial: 25493602
Drug: PrEP (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among women using no hormonal contraception
Trial: 25493602
Drug: PrEP (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among men whose partners used DMPA
Trial: 25493602
Drug: PrEP (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among men whose partners used no hormonal contraception
Trial: 12354427
Drug: l-NMMA (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-NMMA (0.3 mg/kg/min intravenously)
Trial: 9488190
Drug: International Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: International Nifedipine Trial of Antiatherosclerotic Therapy (INTACT)
Trial: 25902885
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (rosuvastatin 5 mg/day + ezetimibe 10 mg/day)
Trial: 25902885
Drug: Monotherapy (rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (rosuvastatin 5 mg/day)
Trial: 24861411
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine + 0.05% cetylpyridinium chloride (CPC) solution
Trial: 20724576
Drug: CHOP-like chemotherapy
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP-like chemotherapy without rituximab
Trial: 7899391
Drug: Pefloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (800 mg + placebo)
Trial: 24206747
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L of PEG3350e with 15 mg bisacodyl
Trial: 20643762
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (CYC)
Trial: 29972884
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg acetylsalicylic acid
Trial: 14764947
Drug: Fructose infusion
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose infusion during ITT
Trial: 9026840
Drug: bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (400 mg/day)
Trial: 6706275
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of codeine and paracetamol
Trial: 6706275
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of codeine and paracetamol
Trial: 12870368
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg twice daily for 10 days
Trial: 15298070
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (TCAs)
Trial: 8694150
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate 0.3 M, 30 ml (group C)
Trial: 8694150
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg IV + Sodium citrate (group MC)
Trial: 8694150
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate + Ranitidine 50 mg IV (group RC)
Trial: 8694150
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate + Omeprazole 40 mg IV (group OC)
Trial: 2868744
Drug: Bucindolol (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bucindolol (50, 100, 200 and 400 mg)
Trial: 6142007
Drug: Pindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (10 mg)
Trial: 202141
Drug: Propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (160 mg)
Trial: 29673735
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug therapy (TDT) with albendazole (400 mg), pyrantel pamoate (20 mg/kg), and oxantel pamoate
Trial: 16565792
Drug: Heparin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin for 24 hours combined with 325 mg acetyl‐acetic acid (Group A)
Trial: 16565792
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ticlopidine twice a day combined with 325 mg acetyl‐acetic acid (Group B)
Trial: 8970140
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ferric sodium citrate
Trial: 8970140
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ferric sodium citrate with 200 mg ascorbic acid
Trial: 8970140
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ferric sodium citrate without vitamin C
Trial: 22464674
Drug: Oral bacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bacterial lysate
Trial: 6204149
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release potassium tablets (64 mmol/day)
Trial: 20927038
Drug: Raloxifene 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 120 mg/day
Trial: 3107602
Drug: lysine acetyl
RxNorm normalized name: Lysine acetylcysteinate
DrugBank: Nacystelyn (DB17839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lysine acetyl salicylate (LAS) 13 mg kg‐1 i.v. 3 min before suxamethonium
Trial: 3107602
Drug: atracurium 0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.09 mg kg‐1
Trial: 26589253
Drug: Dapagliflozin 5
RxNorm normalized name: dapagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 5 mg
Trial: 18026714
Drug: Oral N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral N-acetylcysteine (NAC)
Trial: 20950456
Drug: New DTPw-HBV/Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New DTPw-HBV/Hib vaccine
Trial: 18242706
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of unruptured aneurysms
Trial: 8757567
Drug: r‐HuEPO therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO therapy (20 U/kg body weight, subcutaneously, three times a week for 6 weeks)
Trial: 18496338
Drug: Control (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sham treatment)